연구동향 분석
박사

The development of drug candidate using repositioning for allergic diseases = 약물재창출을 통한 알레르기 질환 치료제 개발에 관한 연구

박영환 2019년

논문상세정보
인용/피인용
' The development of drug candidate using repositioning for allergic diseases = 약물재창출을 통한 알레르기 질환 치료제 개발에 관한 연구' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Allergy
  • Drug repositioning
  • Syk
  • degranulation
  • ige
  • mast cell
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
195 0

0.0%

' The development of drug candidate using repositioning for allergic diseases = 약물재창출을 통한 알레르기 질환 치료제 개발에 관한 연구' 의 참고문헌

  • da Silva, E.Z., Jamur, M.C., Oliver, C. 2014. Mast cell function: a new vision of an old cell. J. Histochem. Cytochem. 62, 698-738.
  • Zabludoff, S.D., et al., 2008. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer. Ther. 7, 2955-2966.
  • Yu, M., et al., 2006. Scaffolding adapter Grb2-associated binder 2 requires Syk to transmit signals from FcεRI, J. Immunol. 176, 2421-2429.
  • Wang, S., et al., 2010. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J. Med. Chem. 53(11), 4367-4378.
  • Vukman, K.V., et al., 2017. Mast cell secretome: soluble and vesicular components. Semin. Cell. Dev. Biol. 67, 65-73.
  • Ulanova, M., et al., 2005. Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis. Expert Opin. Ther. Targets 9, 901-921.
  • Thomas, D.W., et al., 2016. Clinical development success rates 2006-2015. Available at: https://www.bio.org/sites/default/files/Clinical%20Development%20Success% 20Rates%202006- 2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf.
  • Theoharides, T.C., et al., 2012. Mast cell and inflammation. Biochim. Biophys. Acta. 1822(1), 21-33.
  • Theoharides, T.C., et al., 2007. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol. Rev. 217, 65-78.
  • Theoharides, T.C., Kalogeromitros. D., 2006. The critical role of mast cells in allergy and inflammation. Ann. N. Y. Acad. Sci. 1088, 78–99.
  • Thangam, E.B., et al., 2018. The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets. Front. Immunol. 9, 1873.
  • Teramoto, H., et al., 1997. Tyrosine Phosphorylation of the vav Proto-oncogene Product Links FcεRI to the Rac1-JNK Pathway. J. Biol. Chem. 272, 10751– 10755.
  • Siraganian, R.P., et al., 2010. Mast cell signaling: the role of protein tyrosine kinase Syk, its activation and screening methods for new pathway participants. FEBS Lett. 584(24), 4933-4940.
  • Singhal, S., et al., 1999. Antitumor Activity of Thalidomide in Refractory Multiple Myeloma. N. Engl. J. Med. 341, 1565-1571.
  • Siebenhaar, F., et al., 2018. Mast cells as drivers of disease and therapeutic targets. Trends Immunol. 39(2), 151-162.
  • Sanada, S., et al., 2005. The feectiveness of montelukast for the treatment of antihistamine- resistant chronic urticarial. Arch. Dermatol. Res. 297, 134-138.
  • Salojin, K.V., et al., 2000. ZAP-70 Is Essential for the T Cell Antigen Receptorinduced Plasma Membrane Targeting of SOS and Vav in T Cells. J. Biol. Chem. 275, 5966–5975.
  • Saitoh, S.I., et al., 2003. The four distal tyrosines are required for LAT-dependent signaling in FcεRǀ-mediated mast cell activation. J. Exp. Med. 198, 831-843
  • Saitoh, S., et al., 2000. LAT Is Essential for FcεRI-Mediated Mast Cell Activation. Immunity 12, 525-535.
  • Rivera, J., Gilfillan, A.M., 2006. Molecular regulation of mast cell activation. J. Allergy Clin. Immunol. 117(6), 1214-1225.
  • Portnoy, J.M., Dinakar, C., 2004. Review of cetirizine hydrochloride for the treatment of allergic disorders. Expert Opin. Pharmacother. 5(1), 125-135.
  • Pawankar, R., et al., 2013. World Allergy Organization (WAO) White Book on Allergy: Update 2013. World Allergy Organization, Milwaukee.
  • Pawankar, R., et al., 2012. Allergic diseases and asthma: A major global health concern. Curr. Opin. Allergy. Clin. Immunol. 12, 39-41.
  • Parravicini, V., et al., 2002. Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation, Nat. Immunol. 3, 741-748.
  • Park, K.L., et al., 2011. 4-Chlorotetrazolo[1,5-a]quinoxaline inhibits activation of Syk kinase to suppress mast cells in vitro and mast cell-mediated passive cutaneous anaphylaxis in mice. Toxicol. Appl. Pharmacol. 257, 235-241.
  • Ozdemir, C., et al., 2010. T-cell response to allergens. Chem. Immunol. Allergy 95, 22-44.
  • Ozawa, K., et al., 1993. Ca(2+)-dependent and Ca(2+)-independent isozymes of protein kinase C mediate exocytosis in antigen-stimulated rat basophilic RBL- 2H3 cells. Reconstitution of secretory responses with Ca2+ and purified isozymes in washed permeabilized cells. J. Biol. Chem. 268, 1749–1756.
  • Oka, T., Hori, M., Ozaki, H., 2005. Microtubule Disruption Suppresses Allergic Response through the Inhibition of Calcium Influx in the Mast Cell Degranulation Pathway. J. Immunol. 174, 4584-4589.
  • Novac, N., 2013. Challenges and opportunities of drug repositioning. Trends. Pharmacol. 34, 267-272.
  • Nishida, K., et al., 2011. Gab2, via PI-3K, regulates ARF1 in FcεRǀ-mediated granule translocation and mast cell degranulation. J. Immunol. 187, 932-941
  • Nishida, K., et al., 2005. FcεRI-mediated mast cell degranulation requires calciumindependent microtubule-dependent translocation of granules to the plasma membrane. J. Cell Biol. 170, 115–126.
  • Nam, S.T., et al., 2018. Furaltadone suppresses IgE-mediated allergic response through the inhibition of Lyn/Syk pathway in mast cells. Eur. J. Pharmacol. 828, 119-125.
  • Nam, S.T., et al., 2017. Suppression of IgE-mediated mast cell activation and mouse anaphylaxis via inhibition of Syk activation by 8-formyl-7-hydroxy-4- methylcoumarin, 4μ8C, Toxicol. Appl. Pharmacol. 332, 25-31.
  • Moon, T.C., et al., 2014. Mast cell mediators: their differential release and the secretory pathways involved. Front. Immunol. 5, 569.
  • Metcalfe, D.D., et al., 1997. Mast cells. Physiol. Rev. 77(4), 1033-1079.
  • Metcalfe, D.D., Peavy, R.D., Gilfillan, A.M., 2009. Mechanisms of mast cell signaling in anaphylaxis. J. Allergy Clin. Immunol. 124, 639-646.
  • Maier, J.V., 2007. Dual specificity phosphatase 1 knockout mice show enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids. Mol. Endocrinol. 21(11), 2663-2671.
  • MacGlashan, D. Jr., 2009. Therapeutic efficacy of omalizumab. J. Allergy Clin. Immunol. 123, 114-115.
  • Ma, Z., et al., 2012. The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo. Mol. Med. Rep. 6, 897-903.
  • Luik, R.M., et al., 2006. The elementary unit of store-operated Ca2+ entry: local activation of CRAC channels by STIM1 at ER-plasma membrane junctions. J. Cell. Biol. 174(6), 815-825.
  • Liu, Y., et al., 2017. Gemcitabine and Chk1 inhibitor AZD7762 synergistically suppress the growth of Lkb1-deficient lung adenocarcinoma. Cancer Res. 77, 5068-5076.
  • Lieberman, P., Garvey, L.H., 2016. Mast cells and anaphylaxis. Curr. Allergy Asthma Rep. 16, 20.
  • Li. W., et al., 1992. Fc epsilon R1-mediated tyrosine phosphorylation of multiple proteins, including phospholipase C gamma 1 and the receptor beta gamma 2 complex, in RBL-2H3 rat basophilic leukemia cells. Mol. Cell. Biol. 12(7), 3176- 3182.
  • Lee, J.H., et al., 2008. Curcumin, a constituent of curry, suppresses IgE-mediated allergic response and mast cell activation at the level of Syk. J. Allergy Clin. Immunol. 121, 1225-1231.
  • Lee, J.H., et al., 2006. Phospholipase D2 acts as an essential adaptor protein in the activation of Syk in antigen-stimulated mast cells. Blood. 108, 956-964.
  • Lee, J,H., et al., 2011. The Src-family kinase Fgr is critical for activation of mast cells and IgE-mediated anaphylaxis in mice. J. Immunol. 187, 1807-1815.
  • Landau, H.J., et al., 2012. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. Mol. Cancer Ther. 11, 1781-1788.
  • Kov řov , M., et al., 2001. Structure-function analysis of Lyn kinase association with lipid rafts and initiation of early signaling events after Fcɛ receptor I aggregation. Mol. Cell. Biol. 21, 8318-8328.
  • Klemm, S., et al., 2006. The Bcl10-Malt1 complex segregates Fc epsilon RI-mediated nuclear factor kappa B activation and cytokine production from mast cell degranulation. J. Exp. Med. 203, 337-47.
  • Kitakura. J., et al., 2000. Akt-dependent cytokine production in mast cells. J. Exp. Med. 192(5), 729-740.
  • Kim, J.D., et al., 2013. Mours bombycis extract suppresses mast cell activation and IgE-mediated allergic reaction in mice. J. Ethnopharmacol.146, 287-293.
  • Kim, D.K., et al., 2013. The scaffold protein prohibitin is required for antigenstimulated signaling in mast cell. Sci. Signal., 6, ra80.
  • Kim, D.K., et al., 2013. DJ-1 regulates mast cell activation and IgE-mediated allergic responses. J. allergy Clin. Immunol. 131, 1653-1662.
  • Jabril-Cuenod, B., et al., 1996. Syk-dependent phosphorylation of Shc. A potential link between FcεRI and the Ras/mitogen activated protein kinase signaling pathway through SOS and Grb2. J. Biol. Chem. 271, 16268–72.
  • Ito. R., et al., 2013. Establishment of a human allergy model using human IL-3/GMCSF- transgenic NOG mice. J. Immunol. 191(6), 2890-2899.
  • Itamochi, H., et al., 2014. Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary. Int. J. Gynecol. Cancer. 24, 61- 69.
  • Isono, M., et al., 2017. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine. J. Exp. Clin. Canc. Res. 36, 1-12
  • Hoth, M., Penner, R., 1992. Depletion of intracellular calcium stores activates a calcium current in mast cells. Nature 355, 353-356.
  • Hideshima, T., et al., 2000. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 96, 2943-2950.
  • Hang. P.C., Honek, J.F., 2005. Electronic structure calculations on the thiazolecontaining antibiotic thiostrepton: molecular mechanics, semi-empirical and ab initio analyses. Bioorg. Med. Chem. Lett. 15(5), 1471-1474.
  • Hallgren. J., Gurish. M.F., 2007. Pathways of murine mast cell development and trafficking: tracking the roots and routes of the mast cell. Immunol. Rev. 217, 8- 18.
  • Hajduch. M., 2008. In vivo mode of action of CYC116, a novel small molecule inhibitor of aurora kinases and VEGFR2. Cancer Res. 49, Abstract 5645.
  • Grimbaldeston, M.A., 2006. Effector and potential immunoregulatory roles of mast cells in IgE-associated acquired immune response. Curr. Opin. Immunol. 18(6), 751-760.
  • Griffiths, G., et al., 2008. Anti-tumor activity of CYC116, a novel small molecule inhibitor of aurora kinases and VEGFR2. Cancer Res. 49, Abstract 5644.
  • Gilfillan, A.M., Tkaczyk, C., 2006. Integrated signaling pathways for mast-cell activation. Nat. Rev. Immunol. 6, 218-230.
  • Gilfillan, A.M., Rivera, J., 2009. The tyrosine kinase network regulating mast cell activation. Immunol. Rev. 228, 149–169.
  • Galli, S.J., et al., 2005. Mast cells in the development of adaptive immune responses. Nat. Immunol. 6(2), 135-142.
  • Galli, S.J., et al., 2005. Mast cells as “tunable” effector and immunoregulatory cells: recent advances. Annu. Rev. Immunol. 23, 749-786.
  • Galli, S.J., Tsai, M., 2012. IgE and mast cells in allergic disease. Nat. medicine. 18, 693-704.
  • G bly s, A., et al., 2005. Synthesis and biological evaluation of 2-aminothiazoles and their derivatives on human adenosine receptors. Lack of effect of 2- aminothiazoles as allosteric enhancers. Bioorg. Med. Chem. 13(6), 2079-2087.
  • Furumoto, Y., et al., 2006. lentiviral short hairpin RNA silencing of PTEN in human mast cells reveals constitutive signals that promote cytokine secretion and cell survival. J. Immunol. 176(9), 5167-5171.
  • Furumoto, Y., et al., 2004. The FcepsilonRIBeta immunoreceptor tyrosine-based activation motif exerts inhibitory control on MAPK and IkappaB kinase phosphorylation and mast cell cytokine production. J. Biol. Chem. 279(47), 49177-49187.
  • Fu, J., et al., 2007. Roles of Aurora Kinases in Mitosis and Tumorigenesis. Mol. Cancer. Res. 5(1), 1-10.
  • Finkelman, F.D., 2007. Anaphylaxis: Lessons from mouse models. J. Allergy Clin. Immun. 120, 506-515.
  • Das, J., et al., 2006. Discovery and SAR of 2-amino-5-(thioaryl) thiazoles as potent and selective Itk inhibitors. Bioorg. Med. Chem. Lett. 16(14), 3706-3712
  • Cruz, A.A., et al., 2017. Global issues in allergy and immunology: Parasitic infections and allergy. J. Allergy Clin. Immunol. 140, 1217-1228.
  • Costello, P.S., et al., 1996. Critical role for the tyrosine kinase Syk in signaling through the high affinitiy IgE receptor of mast cells. Oncogene. 13, 2595-2605.
  • Bradding, P., et al., 1994. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am. J. Respir. Cell. Mol. Biol. 10, 471-480.
  • Boolell, M., et al., 1996. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for treatment of penile erectile dysfunction. INT. J. IMPOT. RES. 8, 47-52.
  • Beuchet, P., et al., 1999. New 2-sulfonamidothiazoles substituted at C-4: synthesis of polyoxygenated aryl derivatives and in vitro evaluation of antifungal activity. Eur. J. Med. Chem. 34(9), 773-779.
  • Beaven, M.A., Metzger, H., 1993. Signal transduction by Fc receptors: the FcεRI case. Immunol. Today. 14, 222-226.
  • Beaven, M.A., 2009. Our perception of the mast cell from Paul Ehrlich to now. Eur. J. Immunol. 39, 11–25.
  • Baba, Y., et al., 2006. Coupling of STIM1 to store-operated Ca2+ entry through its constitutive and inducible movement in the endoplasmic reticulum. Proc. Natl. Acad. Sci. U.S.A. 103(45), 16704-16709.
  • Ashburn, T.T., Thor, K.B., 2004. Drug repositioning: Identifying and developing new uses for existing drugs. Nat. Rev. Drug. Discov. 3, 673-683.